Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 17/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479206 | 0.85 | NR1H4 (0.48) | GRM5NR1H4 | |
| SCHEMBL8272720 | 0.84 | NR1H4 (0.68) | GRM5NR1H4 | |
| SCHEMBL8245030 | 0.84 | NR1H4 (0.68) | GRM5NR1H4 | |
| SCHEMBL8272755 | 0.84 | NR1H4 (0.68) | GRM5NR1H4 | |
| SCHEMBL5955781 | 0.83 | NR1H4 (0.46) | GRM5NR1H4MAOB | |
| SCHEMBL4071767 | 0.83 | NR1H4 (0.69) | GRM5NR1H4 | |
| Hydrochloric Acid SCHEMBL4956639 | 0.83 | NR1H4 (0.67) | GRM5NR1H4 | |
| Hydrochloric Acid SCHEMBL4955423 | 0.83 | NR1H4 (0.67) | GRM5NR1H4 | |
| Hydrochloric Acid SCHEMBL4955420 | 0.83 | NR1H4 (0.67) | GRM5NR1H4 | |
| SCHEMBL5781394 | 0.81 | NR1H4 (0.46) | GRM5NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-7074809-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | disclosed |
| EP-1581525-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20040106607-A1 | New compounds | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004014902-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | GRM5 5/4885NR1H4 217/4885KCNH2 359/4885 |
| US-20040106607-A1 | New compounds | MTX1, MLX, TPX2 | GRM5 414/4885NR1H4 372/4885KCNH2 1251/4885 |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | GRM5 4/4885NR1H4 200/4885KCNH2 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.